HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of ET(A) and ET(B) receptor blockade on post-ischemic cardiac dysfunction and norepinephrine overflow in isolated rat hearts.

Abstract
We investigated the role of endothelin-A (ETA) and endothelin-B (ETB) receptors in ischemia/reperfusion-induced cardiac dysfunction and norepinephrine overflow using isolated rat hearts. According to the Langendorff technique, isolated hearts were subjected to 40 minutes of global ischemia followed by 30 minutes of reperfusion. Ischemia/reperfusion led to decreases in left ventricular developed pressure and coronary flow, and an increase in left ventricular end-diastolic pressure compared with pre-ischemic basal levels. An ETB receptor antagonist A-192621 at 1 microM worsened ischemia/reperfusion-induced cardiac dysfunction. In contrast, an ETA receptor antagonist ABT-627 at 5 microM with or without A-192621 improved the aforementioned cardiac dysfunction, to the same extent. Norepinephrine was massively released in coronary effluent from the hearts exposed to ischemia/ reperfusion. Treatment with ABT-627 significantly suppressed the norepinephrine overflow induced by the ischemia/reperfusion whereas A-192621 further enhanced it, which was completely abolished by the concomitant treatment with ABT-627. These results suggest that the detrimental effect of ETB receptor blockade on post-ischemic cardiac function is mediated by the ETA receptor-related action and that norepinephrine overflow from sympathetic nerve endings is closely related to the antagonist-induced functional changes of post-ischemic hearts.
AuthorsSatoshi Yamamoto, Noriko Matsumoto, Mitsuo Kanazawa, Marie Fujita, Masanori Takaoka, Yasuo Matsumura
JournalJournal of cardiovascular pharmacology (J Cardiovasc Pharmacol) Vol. 44 Suppl 1 Pg. S394-7 (Nov 2004) ISSN: 1533-4023 [Electronic] United States
PMID15838330 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • A 192621
  • Cardiovascular Agents
  • Endothelin A Receptor Antagonists
  • Endothelin B Receptor Antagonists
  • Pyrrolidines
  • Receptor, Endothelin A
  • Receptor, Endothelin B
  • Atrasentan
  • Norepinephrine
Topics
  • Animals
  • Atrasentan
  • Cardiovascular Agents (pharmacology)
  • Coronary Circulation (drug effects)
  • Drug Therapy, Combination
  • Endothelin A Receptor Antagonists
  • Endothelin B Receptor Antagonists
  • In Vitro Techniques
  • Male
  • Myocardial Reperfusion Injury (drug therapy, metabolism, physiopathology)
  • Myocardium (metabolism)
  • Norepinephrine (metabolism)
  • Pyrrolidines (pharmacology)
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Endothelin A (metabolism)
  • Receptor, Endothelin B (metabolism)
  • Sympathetic Nervous System (drug effects, metabolism)
  • Time Factors
  • Up-Regulation
  • Ventricular Dysfunction, Left (drug therapy, metabolism, physiopathology)
  • Ventricular Pressure (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: